www射-国产免费一级-欧美福利-亚洲成人福利-成人一区在线观看-亚州成人

US EUROPE AFRICA ASIA 中文
Business / Industries

Stem cells offer ray of hope for healthy future

By Alfred Romann in Seoul For China Daily (China Daily) Updated: 2014-06-23 07:08

Regenerative medicine sector needs more financial support from private investors

One of the most important and innovative pharmaceutical companies in Asia has its headquarters in a busy neighborhood of Seoul, nestled between insurance companies and banks, and not far from Seoul National University.

Medipost Co Ltd, launched in 2000 to research and develop stem cell and regenerative medicine products, has emerged as a leader in the space, both regionally and globally. It took a dozen years for the company to launch its first product commercially: Cartistem used to treat repair cartilages in the knee.

Between its founding and its first product launch, Medipost issued new shares six times and split its stock once. It generated some further revenue, mostly by storing umbilical cord blood, using the blood to transplant stem cells, and later by out-licensing products.

But that income was tiny compared to the cost of developing its drugs. Improbably, it managed to attract enough investors to keep going and growing.

That investment is now starting to pay off. Cartistem is just one of three stem cell products approved for sale in South Korea, and Medipost might be the only public company in the country with global ambitions.

"There are not many companies that can deal with global development in the pharmerging market," said Jay Lee, a senior director at Medipost, speaking at a conference in South Korea last month.

The "pharmerging" markets are the emerging markets for pharmaceutical products. China is possibly the biggest, but there are quite a few of them in the region including South Korea and much of the Association of Southeast Asian Nations.

Even Japan, despite its large economy, is considered an emerging market in some ways because it is often years before drugs developed elsewhere make their way down to patients there due to conservative regulations.

But much is changing in the region, particularly in South Korea and Japan. Both countries are embracing often-controversial research into regenerative medicine, including stem cells.

"There is an exceptional example of a new approach in Japan. They are looking very much, as in South Korea, to develop the stem cell space," says Dianne Jackson-Matthews, an Australia-based director at ERA Consulting Group.

For the time being, government support is driving the growth of this particular industry. Private or institutional investors are not yet convinced that taking a risk on a company developing a drug using science few people understand is worthwhile.

Stem cells offer ray of hope for healthy future

Stem cells offer ray of hope for healthy future

 Stem Cell Industrial Park under construction in Wenjiang  Medical experts call for effective stem cell treatment regulation

Previous Page 1 2 3 Next Page

Hot Topics

Editor's Picks
...
...
主站蜘蛛池模板: 美女张开腿让人桶 | 中文字幕一区二区三区久久网站 | 色综合美国色农夫网 | 97国产在线观看 | 日韩在线精品 | 精品a在线观看 | 国产女厕所 | 欧美成人免费一级人片 | 国产欧美日韩综合精品无毒 | 成年网站在线在免费播放 | 亚洲在线精品视频 | 亚洲欧美一二三区 | 久久精品中文字幕一区 | 亚洲国产成人久久一区久久 | 欧美精品在线免费观看 | 久久免费视频精品 | 国产午夜不卡在线观看视频666 | 寡妇野外啪啪一区二区 | 欧美又粗又硬又大久久久 | 久久99国产精品亚洲 | 一区二区三区四区产品乱码伦 | 久久精品夜色国产 | 欧美大胆a| 国产日韩视频在线观看 | 91老色批网站免费看 | 久久99亚洲精品一区二区 | 成人毛片国产a | 一区二区三区高清视频在线观看 | 欧美人成在线观看ccc36 | 国产一区二区日韩欧美在线 | 亚洲欧美日韩综合二区三区 | 国自产精品手机在线视频香蕉 | 欧美老熟妇bbbb毛片 | 午夜黄色福利视频 | 男女那个视频免费 | 国产成人一区二区三中文 | 亚洲一区二区三区成人 | 久久久久久久国产免费看 | 色综合久久久高清综合久久久 | 在线一区二区三区 | 99久久精品久久久久久清纯 |